Susan Jones Kalota, M.D.
Arizona Medical License: 20774
1975 - 1980 University of California San Diego – B.S. in Biology
1977 - 1978 Jr.Year Education Abroad Program: Pau & Paris, France
1982 - 1986 Howard University College of Medicine: Washington, D.C. 1986 - 1988 University of California San Diego – Surgery Internship 1988 - 1992 University of California San Diego – Urology Residency
Observer at Institute of Urology – London, England
Parsons, C.L., Boychuk, D., Jones, S.M., Hurst, R. and Callahan, H. – Bladder
surface glycosaminoglycans: an epithelialpermeability barrier. JUrol 143: 139-142 1990. Jones, S.M., Parsons, C.L. and Stein, P. – Prevention of acrolein inducted bladder
injury by pentosanpolysulfate, JUrol 143(4): 280A 1990. Jones, S.M., Stein, P.C. and Parsons, C.L. - Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 148(1) 163 – 166 1990.
Jones, S.M. – The Injured Bladder AUA Today. Jones, S.M., Greene, L.F. and Parsons, C.L. – Evaluation of the urologic patient.
The Practice of Urology W.W. Norton & Co. New York, NY 1992 Bidar, M., Kalota, S.M. and Kaplan, G.W. – Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? JUrol 150(1) 153-155.
Stratasis Small Intestinal Submucosa Tension-Free Sling Case Report JUro
172(4): 1349 – 1350 October 2004. Presentations
Jones, S.M. and Parson, C.L. – Prevention of acrolein-induced bladder injury
pentosanpolysulfate. AUA 85th Annual Meeting. New Orleans, LA May 1990.
Jones, S.M. The in’s and out’s of GU Bleeding, Presented to Southern California
Chapter of the American Urologic Association Allied. San Diego, CA September 1991. Speaker for Pfizer, Bayer and Ortho-McNeil
Alza Pharmaceutical Speaker’s Bureau 1999 – 2001 Nurse Practitioners Annual Convention - San Diego, CA 2000
Private Practice Gynecologist on simple cystitis - San Francisco, CA 2000 Multiple Community Presentations for Physicians and Lay Persons Consortium of Multiple Sclerosis Centers- Atlanta, GA 2009
Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient
Consortium of Multiple Sclerosis Centers- San Antonio, TX 2010 Gender Specific Concerns in MS: Urologic manifestation of MS In the male
patient Awards and Honors
1982 - 1984 Academic Achievement Award for academic excellence at Howard
Nomination to AOA Medical Honor Society – V.P. of Gamma
American Medical Women’s Association – Scholarship
Department of Surgery honorable mention for scholastic
Department of Medicine honorable mention for scholastic
Ralph C. Kennedy, M.D. Award for highest score in Psychiatry on
Merck Manual Award for highest scholastic records
Federal Drug Administration – Gastroenterology and Urology Devices Panel Member - Center for Devices & Radiological Health (CDRH) Office of Device
Evaluation (ODE) Division of Reproductive, Abdominal and Radiological Devices (DRARD) Gastroenterology and Renal Devices Branch (GRDB) 2004 - 2008
Stress Incontinence, Study Phase 2, 1998 Urge Incontinence, Study Phase 3B, 8 patients enrolled/27 months long, 1999 Quality of Life Study for Overactive Bladder Phase 4, 18 patients enrolled 8 weeks
long. Pharmacia/Upjohn, 2001 Overactive Bladder Study Phase 3B, 6 patients enrolled/12 weeks long/Pharmacia/Upjohn, 2001
Urogenital Symptoms in Post Menopausal Women Study Phase 4, 2001 Phase 4 Overactive Bladder/Pfizer/PPD with Rapid Trials, 2004
Sanofi-Synthelabo BPH Registry, 22 patients enrolled, 2004 Watson Quality of Life Study for Oxytrol in OAB 2004, 33 patients enrolled, 2004 Phase 3/AstraZeneca/ Jupiter/LDL and C-Reaction Protein/Cholesterol, 2004
Pharmatech/ Phase 3/ Advanced Prostate Cancer, 2004 Odyssey Pharmaceuticals/ Phase 4/ Overactive Bladder, 2005 AstraZeneca/ Overactive Bladder/ Phase 3, 2005
Nymox/ Phase 2/ Benign Prostatic Hyperplasia, 2005 Praecis/ INC Research/Prostate Cancer/ Phase 3, 2005
Indevus/ Double-Blind and Open-Label Drug for OAB, 2005 Pfizer/Phase 2/Stress Incontinence/ 2006 Astellas/ Phase 4/OAB pts with Sx’s of BPH/2006
Nymox/ Phase2/ Benign Prostatic hypertrophy/2007 Astellas/ Phase 2/ Male subjects with LUTS and BOO/2007
Solace Therapeutics/An evaluation of the AttnueX Intravesical System in the Management of Female Patients with Stress Urinary Incontinence/2007
AMS/The Prolapse Registry: An Observational Collection of Short- and Long-Term
Patient Outcomes Following Use of AMS Surgical Devices for the Repair Of Female Genital Prolapse./2007 Astellas /047 Phase III Double Blind Placebo Controlled/ OAB Study /2008
Astellas/ 049 Phase III Double Blind Placebo Controlled / OAB Study/2008 Uroplasty/ Study of Urgent PC Vs. Sham Effectiveness in Treatment of OAB/ 2008
Astellas/074 Phase III Double Blind, Parallel Group, Placebo Controlled/ OAB Study/2009
Nymox/ Phase III Randomized Parallel-Group Placebo Controlled, Double Blind Clinical Evaluation/Treatment of BPH/2009
Pfizer/ 13Week Single Arm, Open Label, Multicenter Study to Evaluate Refill Adherence And Satisfaction with Fesoterodine Plus “Your Way” Patient Support Plan” in
Patients with Symptoms of OAB/2009 Allergan 191622-095/A Multicenter, Double-Blind, Randomized, Placebo-
Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin A) Purified Neurotoxin Complex Followed by a Treatment
With Botox as Applicable in Patients with Idiopathic Overactive Bladder and Urinary Incontinence. Allergan 191622.096/ A Multicenter, Long-Term Follow-up Study of Safety and
Efficacy of the Safety and Efficacy of Botox (Botulinum Toxin Type-A) Purified
Neurotoxin Complex in Patients with Idiopathic Overactive Bladder and Urinary Incontinence.
A Randomized, Parallel Arm, Open-Label Trial
Comparing Degarelix With Goserelin Plus Anti- Androgen Flare Protection, In Terms Of Prostate Size Reduction In Prostate Cancer Patients Of Intermediate –To- High Risk, Who Require Neoadjuvant Hormone Therapy Prior To
Endo (EN3348-303)/ A Phase 3, Randomized, Active-Controlled, Open-Label,
Multicenter Study To Evaluate The Efficacy And Safety Of EN3348 (MCC) As Compared With Mitomycin C In The Intravesical Treatment Of Subjects With
BCG Recurrent Or Refractory Non-Muscle Invasive Bladder Cancer.
Pfizer A0221049/ A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine
Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. Ethicon Endo Surgery, Inc (CI-10-0009) Multi-center, prospective, randomized,
double-blind, sham-controlled clinical study to evaluate safety and effectiveness of a transcutaneous, high-frequency, amplitude-modulated, non-invasive neuromodulation device on urgency urinary incontinence in subjects with
12/2001 Recertification - Diplomate American Board of Urology
Southern Arizona Urologic Society
Arizona Urologic Society member 1992 – present
Western Section of American Urologic Association member 1992 – present American Urologic Association member 1988 – present
Health Policy Committee 1999 – 2000 Committee on Women’s Issues in Urology 1999 – 2000 Society of Woman in Urology 1992 – present
President 1999 – 2000 President-elect 1998 – 1999 Board of Directors 1997 – 1998
Tucson Society of Woman Physicians 1993 - present
Founding President 1993 – 1994 Secretary/Treasurer 1994 – present
Pima County Medical Society 1992 – present
Secretary/Treasurer 2001 Board of Directors 1999 – 2001 Board of Directors 1996 – 1998
Arizona Medical Association 1999 – present ArMA Committee on Insurance Reform 1999 – 2000
Scientific Advisory Board for Novasys Medical Practice Experience
Group Practice General Urology- Urological Associates of Southern Arizona, Tucson, AZ
8/1992 – 04/2011 Private Practice General Urology- Arizona Urologic
Urology Resident – University of California San Diego
General Surgery Internship & Residency – University of California San Diego
Urology Research –University of California San Diego. Study in vivo urea movement across treated bladder epithelium and in-vitro urinary bladder transport.
Medical Study Tutor – Anatomy, Microbiology and Pathophysiology
Quality Assurance Specialists: Developed Quality Assurance Instruction Manual for General Dynamics – Los Angeles, CA
Research Associate – University of California San Diego.
Department of Community Medicine study of nutrition and prenatal risk factors to pregnancy outcome.
NIKP-GLIMEPIRIDE TABLET 3mg Nichi-Iko unconsciousness. The clinical picture of severe reduced blood sugar level Taking NIKP-GLIMEPIRIDE with food and drink Tell your doctor immediately if you experience any of the following Glimepiride 3mg Alcohol intake may increase or decrease the blood sugar lowering action of symptoms: NIKP-GLIMEPIRIDE in an unpredictable way. Allergic
LIMERICK COUNTY COUNCIL P L A N N I N G A P P L I C A T I O N S PLANNING APPLICATIONS GRANTED FROM 27/07/2009 TO 31/07/2009 in deciding a planning application the planning authority, in accordance with section 34(3) of the Act, has had regard to submissions or observations recieved in accordance with these Regulations; that it is the responsibility of any person wishing to use the